Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

People living with motor neuron disease (MND) will have more opportunities to participate in groundbreaking research, thanks ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Early in his career he devised a contraption capable of distinguishing certain mineral signatures underground, and he later took part in one of the high adventures of Canada’s storied mining history ...

Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...

Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments ...

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...